In 2008, sunitinib and sorafenib were approved in Japan and since then, molecular targeted drugs have been used in stan-＊ 2-2-2, Iida-Nishi, Yamagata-shi, Yamagata 990-9585, Japan Jpn J Pharm Health Care Sci 43(5) 245-251 (2017) Sunitinib and sorafenib as well as interferon-α (IFN-α) are first-line therapies for advanced or recurrent renal cell carcinoma. Although the efficacy of molecular targeted drugs appears indisputable, some research suggests that they are not significantly effective compared to cytokine therapies in terms of progression-free survival. The therapeutic effects of new drugs depend on the decision of doctors and hospitals, which is partially based on the evaluation of costeffectiveness of these therapies. The purpose of this study was to analyze the clinical decisions involved in selecting IFN-α, sunitinib, and sorafenib regimens and to identify the best regimen for the first-line treatment of advanced or recurrent renal cell carcinoma based on clinical and economic evidence. The health outcomes of the therapies considered in this study were analyzed based on the literature on randomized controlled clinical trials of the drugs. The total costs of the regimens were calculated on the basis of direct costs obtained from medical records of patients diagnosed with advanced or recurrent renal cell carcinoma at Yamagata University Hospital. Cost-effectiveness was analyzed by the Markov chain Monte Carlo (MCMC) method. The study was designed from a social viewpoint. The MCMC analysis revealed that the incremental cost per effectiveness ratios of sunitinib and sorafenib to IFN-α were 746,919 yen and 421,930 yen per life month, respectively. Molecular targeted drugs are superior to IFN-α in terms of health outcomes but are less cost-effective.
Introduction
Renal cell carcinoma patients are estimated to account for 1-2％ of all adult carcinoma patients and 20-30％ of them have metastases at diagnosis. 1) Cytokines such as interferon-α (IFN-α) or interleukin-2 were the primary treatment options for metastatic renal cell carcinoma. However, they had limited ef cacy and the median overall survival (OS) after metastasis diagnosis was approximately 1 year.
2)
Regular Article dard regimens for metastatic renal cell carcinoma.
These drugs have improved prognostic outcomes and prolonged the median OS to approximately 3 years. 3, 4) Sunitinib and sorafenib are receptor tyrosine kinase inhibitors and affect vascular endothelial growth factor receptors. Both are approved in Japan as rst-line treatment drugs for advanced or recurrent renal cell carcinoma. However, some research suggests that there is no signi cant difference in the progression-free survival (PFS) between cytokine therapies and molecular targeted therapies. 5) The therapeutic effects of new drugs depend on the decision of doctors and hospitals, which is partly based on the evaluation of costeffectiveness of these therapies. 
Evaluation of health outcomes
Based on the results of randomized controlled clinical trials of IFN-α, sunitinib, and sorafenib treatments for advanced or recurrent renal cell carcinoma, health outcomes (OS and PFS) were evaluated [6] [7] [8] [9] [10] [11] and the transition probabilities between the three health states in Markov model were calculated.
Resource use and costs
Medical records and receipts were used to 
Evaluation of cost-effectiveness
We used the life months gained as health out- The transition probability from progress-free to post-progress was 12.26％ for IFN-α, 5.80％ for sunitinib, and 9.30％ for sorafenib and that from post-progress to death was 3.13％, 2.30％, and 2.96％, respectively. Tables 3 and 4 Table 5) .
Results

Health outcomes
Costs
Discussion
Since the approval of sunitinib and sorafenib in 
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